Oral Biologics Push Forces Rethink of Formulation and Manufacturing

The accelerating pipeline of oral biologics and macrocycle drugs is forcing pharmaceutical manufacturers to confront a new set of formulation, process validation, and scale-up challenges that differ fundamentally from traditional small-molecule or injectable biologic production. With programs such as Johnson & Johnson's macrocycle Icotyde and Merck's oral PCSK9 antagonist Enlicitide advancing through development, large pharma companies are increasingly building in-house capabilities to support this emerging drug class, signaling a shift that plant heads and QA directors should be preparing for now.

The strategic interest from major pharmaceutical companies in oral biologic platforms reflects a recognition that the field is approaching a turning point. Macrocycle drugs, which occupy a chemical space between small molecules and large biologics, demand manufacturing approaches that do not fit neatly into existing GMP frameworks designed for either category. Facilities accustomed to conventional oral solid dosage or parenteral biologic production may need to evaluate new unit operations, analytical methods, and process controls to accommodate these complex molecules while maintaining compliance with ICH Q10 quality management principles and applicable regulatory expectations.

According to Morten Graugaard, the next generation of macrocycle drug design will require the field to evolve beyond its current capabilities. This evolution encompasses not only medicinal chemistry and molecular design but also downstream formulation science, where oral delivery of large, complex molecules presents well-documented bioavailability and stability challenges. For QA and regulatory affairs teams, this means anticipating new questions around process validation protocols, dissolution testing strategies, and specification-setting for drug products that behave differently from established oral dosage forms.

For manufacturing sites, the practical implications are significant. Oral biologics and macrocycles may require specialized containment, novel excipient handling, and tighter environmental controls during production. Process development teams will need to establish robust design spaces early, and technology transfer from development to commercial scale will demand close collaboration between R&D, manufacturing, and quality functions. Regulatory affairs leads should monitor how agencies such as the FDA and EMA develop guidance specific to this drug class, as current frameworks may not fully address the unique attributes of orally delivered macromolecules.

The source interview with Graugaard was published by Pharmaceutical Industry News on April 17, 2026.